NIOX Group
 | |
| Company type | Public limited company |
|---|---|
| LSE: CIR | |
| Industry | Pharmaceuticals |
| Founded | 2006 |
| Headquarters | Oxford, United Kingdom |
Key people | Francesco Granata, (Chairman) Steven Harris, (CEO) |
| Revenue | £10.8 million (2015)[1] |
| £(66.4) million (2015)[1] | |
| £(50.0) million (2015)[1] | |
| Website | www.circassia.co.uk |
Circassia Pharmaceuticals is a specialty biopharmaceutical company developing a range of immunotherapies. It is listed on the London Stock Exchange.
History
The company was founded by Steve Harris and Charles Swingland in 2006.[2] It was the subject of an Initial Public Offering in March 2014.[3]
Operations
The company's technology, ToleroMune, was initially developed by scientists at Imperial College London.[2] The company is in the process of developing a treatment for cat allergies.[4]
References
- ^ a b c "Accounts for year ended 31 December 2015". Circassia Pharmaceuticals. Retrieved 31 March 2016.
- ^ a b "Fundamentals for Circassia Pharmaceuticals Ord 0.08p". The Telegraph. Retrieved 23 August 2014.
- ^ "Circassia IPO Fuels Optimism on European Biotech". Wall street Journal. 13 March 2014. Retrieved 23 August 2014.
- ^ "Hope of cat allergy cure brings Circassia to stock market". The Telegraph. 6 February 2014. Retrieved 23 August 2014.